Quadracel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of national immunization programs, improved vaccine manufacturing capabilities, increased public health awareness, availability of combination vaccine formulations, growth in pediatric healthcare infrastructure.

The growth in the forecast period can be attributed to increasing focus on global vaccination coverage, rising investments in pediatric vaccine development, expansion of government-backed immunization initiatives, growing demand for combination vaccines, advancements in vaccine formulation technologies. Major trends in the forecast period include increasing adoption of combination pediatric vaccines, rising focus on immunization schedule simplification, growing emphasis on vaccine safety and efficacy, expansion of routine childhood vaccination programs, enhanced cold-chain vaccine distribution.

The rising incidence of vaccine-preventable diseases is expected to drive the growth of the Quadracel market in the coming years. Vaccine-preventable diseases (VPDs) are infectious illnesses for which effective vaccines exist to prevent illness, complications, and fatalities. The increase in VPDs is a significant public health concern, influenced by factors such as gaps in vaccination coverage, evolving pathogens, and societal challenges. Quadracel plays a key role by providing protection against multiple vaccine-preventable diseases in a single dose, helping reduce the burden of these illnesses and improving public health outcomes. For example, in August 2024, the UK Health Security Agency (UKHSA) reported 368 measles cases in England in 2023, a nearly sevenfold increase from 53 cases in 2022, with the West Midlands and London accounting for 44% and 33% of cases, respectively. This trend underscores how the rising incidence of vaccine-preventable diseases is fueling the growth of the Quadracel market.

The increasing prevalence of infectious diseases is also expected to propel the growth of the Quadracel market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which invade the body and multiply, leading to symptoms and potentially severe health complications. Factors driving the rise in infectious diseases include antimicrobial resistance (AMR), globalization and urbanization, climate change, and insufficient vaccination coverage. Quadracel helps combat infectious diseases by offering a combination vaccine that protects against four major infections: diphtheria, tetanus, pertussis, and polio. For instance, in December 2024, the Centers for Disease Control and Prevention (CDC) reported that pertussis cases in the United States had increased more than sixfold by week 47 (November 30, 2024) compared to the same period in 2023, reflecting a return to typical trends. Consequently, the rising prevalence of infectious diseases is contributing to the expansion of the Quadracel market.

Growing government initiatives are further expected to boost the growth of the Quadracel market. These initiatives are driven by public health concerns, rising healthcare costs, global health challenges, and public demand for better healthcare services. Government actions are critical in promoting Quadracel by ensuring its availability, affordability, and widespread vaccination to prevent multiple infectious diseases. For example, in May 2024, the United States Department of Health and Human Services (HHS) reported that the President’s Fiscal Year 2024 Budget aimed to advance HHS’s mission of promoting the health and well-being of Americans. The budget proposed $144.3 billion in discretionary funding and $1.7 trillion in mandatory funding for FY 2024, up from $131.8 billion and $1.5 trillion, respectively, in FY 2022. These increasing government initiatives are supporting the growth of the Quadracel market.

Major companies operating in the quadracel market are Sanofi Pasteur Limited.

North America was the largest region in the quadracel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the quadracel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quadracel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the quadracel market by increasing costs of imported vaccine manufacturing equipment, sterile filling systems, cold-chain storage units, and specialized raw materials used in combination vaccine production. North America and Europe are most affected due to reliance on global vaccine supply chains, while developing regions face higher procurement costs. These tariffs increase production and distribution expenses for pediatric vaccines. However, they are also encouraging domestic vaccine manufacturing, regional fill-finish expansion, and strengthened public-private partnerships to improve long-term vaccine supply resilience.

The quadracel market research report is one of a series of new reports that provides quadracel market statistics, including quadracel industry global market size, regional shares, competitors with a quadracel market share, detailed quadracel market segments, market trends and opportunities, and any further data you may need to thrive in the quadracel industry. This quadracel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Quadracel is a combination vaccine designed to immunize children aged 4 to 6 years against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. It includes inactivated poliovirus and acellular pertussis components, ensuring both safety and effectiveness. Approved for routine pediatric use, it streamlines immunization schedules by delivering multiple antigens in a single dose.

The primary types of Quadracel include the DTaP-IPV vaccine and other combination vaccines. The DTaP-IPV vaccine protects against diphtheria, tetanus, pertussis, and polio and is generally administered to children. It is indicated for the prevention of diphtheria, tetanus, pertussis, and poliomyelitis. Quadracel is utilized in pediatric and adult vaccination programs, traveler immunizations, and healthcare worker vaccinations, and is employed by various end users such as hospitals, clinics, vaccination centers, government health initiatives, and private healthcare providers.

The quadracel market consists of sales of products such as combination vaccines and single-dose vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.